AKT1 and melanoma: ISL treatment significantly inhibited A375 melanoma cell proliferation, induced G2/M cell cycle arrest, and up-regulated terminal melanocyte differentiation indicators, and significantly decreased melanoma cachexia through decreasing the protein expression levels of activated mTORC2-Akt-GSK3β signaling pathway components.